Table 1.
Baseline characteristics of the patients with Ad-hepatocellular carcinoma who received camrelizumab plus apatinib and hepatic artery infusion chemotherapy therapy
| Variables |
Unmatched
|
PSM (1:1)
|
||||
|
TRIPLET alone group (n = 122)
|
TRIPLET-MWA group (n = 95)
|
P value
|
TRIPLET alone group (n = 82)
|
TRIPLET-MWA group (n = 82)
|
P value
|
|
| Age, year | 0.930 | 1.000 | ||||
| ≤ 65 | 112 (91.80) | 86 (90.53) | 76 (92.68) | 77 (93.90) | ||
| > 65 | 10 (8.20) | 9 (9.47) | 6 (7.32) | 5 (6.10) | 1.000 | |
| Gender | 0.505 | |||||
| Female | 12 (9.84) | 13 (13.68) | 8 (9.76) | 9 (10.98) | 1.000 | |
| Male | 110 (90.16) | 82 (86.32) | 74 (90.24) | 73 (89.02) | ||
| ECOG | 0.900 | 1.000 | ||||
| 0 | 122 (100.00) | 94 (98.95) | 82 (100.00) | 81 (98.78) | ||
| 1 | 0 (0.00) | 1 (1.05) | 0 (0.00) | 1 (1.22) | ||
| Comorbidity | 1.000 | 0.677 | ||||
| Absence | 110 (90.16) | 86 (90.53) | 75 (91.46) | 74 (90.24) | ||
| Presence | 12 (9.84) | 9 (9.47) | 7 (8.54) | 8 (9.76) | ||
| HBV | 0.407 | 1.000 | ||||
| Absence | 6 (4.92) | 2 (2.11) | 4 (4.88) | 2 (2.44) | ||
| Presence | 116 (94.26) | 93 (95.79) | 78 (95.12) | 80 (97.56) | ||
| Ascites | 0.011a | 1.000 | ||||
| Absence | 93 (76.23) | 87 (91.58) | 75 (91.46) | 75 (91.46) | ||
| Presence | 29 (22.95) | 8 (8.42) | 7 (8.54) | 7 (8.54) | ||
| ALBI grade | 0.041a | 0.867 | ||||
| 1 | 67 (54.92) | 66 (69.47) | 55 (67.07) | 57 (69.51) | ||
| 2-3 | 55 (45.08) | 29 (30.53) | 27 (32.93) | 25 (30.49) | ||
| HCC number | 0.277 | 0.219 | ||||
| 1-3 | 54 (44.26) | 50 (52.63) | 50 (70.42) | 42 (59.15) | ||
| > 3 | 68 (55.74) | 45 (47.37) | 21 (29.58) | 29 (40.85) | ||
| HCC diameter, cm | 0.667 | 0.155 | ||||
| < 5 | 7 (5.74) | 6 (6.32) | 7 (8.54) | 4 (4.88) | ||
| 5-10 | 51 (41.80) | 34 (35.79) | 41 (50.00) | 32 (39.02) | ||
| > 10 | 64 (52.46) | 55 (57.89) | 34 (41.46) | 46 (56.10) | ||
| AFP, ng/mL | 0.605 | 0.428 | ||||
| ≤ 400 | 46 (37.70) | 40 (42.11) | 31 (37.80) | 37 (45.12) | ||
| > 400 | 76 (62.30) | 55 (57.89) | 51 (62.20) | 45 (54.88) | ||
| Vascular invasion | 0.077 | 0.346 | ||||
| Absence | 18 (14.75) | 24 (25.26) | 15 (18.29) | 21 (25.61) | ||
| Presence | 104 (85.25) | 71 (74.74) | 67 (81.71) | 61 (74.39) | ||
| Metastasis | 0.750 | 0.158 | ||||
| Absence | 68 (55.74) | 50 (52.63) | 50 (60.98) | 40 (48.78) | ||
| Presence | 54 (44.26) | 45 (47.37) | 32 (39.02) | 42 (51.22) | ||
| AST (U/L), median, IQR | 67 (31, 105) | 77 (32, 112) | 0.854 | 85 (28, 128) | 77 (35, 127) | 0.872 |
| ALT (U/L), median, IQR | 54 (22, 89) | 59 (22, 89) | 0.746 | 58 (22, 89) | 59 (25, 109) | 0.929 |
| TBIL (μmol/L), mean ± SD | 17.8 | 23.2 | 0.422 | 18.6 | 19.0 | 0.710 |
| ALB (g/L), mean ± SD | 37.0 ± 5.1 | 37.6 ± 4.2 | 0.564 | 37.2 ± 53 | 37.0 ± 4.2 | 0.567 |
| INR, mean ± SD | 1.1 ± 0.12 | 1.12 ± 0.10 | 0.901 | 1.10 ± 0.14 | 1.11 ± 0.10 | 0.892 |
| PT (s), mean ± SD | 12.4 ± 0.3 | 12.3 ± 0.6 | 0.940 | 12.4 ± 0.8 | 12.4 ± 0.6 | 1.000 |
| PLT (× 109), median, IQR | 208(59, 245) | 256 (67, 312) | 0.358 | 230 (55, 270) | 256 (78, 304) | 0.660 |
P value < 0.05 suggest statistically significant differences.
Data are number of patients; data in parentheses are percentage unless otherwise indicated. Data in bracket was percent of patients. The quantitative data with mean ± SD or median with interquartile range were compared by the Kruskal-Wallis test. The qualitative data in two groups were compared by using the χ2 test. HCC: Hepatocellular carcinoma; TRIPLET: Camrelizumab plus apatinib and hepatic artery infusion chemotherapy; MWA: Microwave ablation; PSM: Propensity score match; ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; AFP: α-fetoprotein; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PT: Prothrombin time; INR: International normalized ratio; TBIL: Total bilirubin; PLT: Platelet; IQR: Interquartile range.